MINI FUTURE LONG - ABIVAX | Market Closed - Börse Stuttgart 15:28:00 02/07/2024 BST | ||
| 8.6 EUR | +4.12% |
|
| Current month | +13.76% | ||
| 1 month | +9.28% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ABIVAX
| Date | Price | Change |
|---|---|---|
| 02/07/24 | 8.6 | +4.12% |
| 01/07/24 | 8.26 | +9.26% |
| 28/06/24 | 7.56 | -2.83% |
| 27/06/24 | 7.78 | -1.52% |
| 26/06/24 | 7.9 | -8.56% |
Delayed Quote Börse Stuttgart
Last update July 02, 2024 at 03:28 pm
More quotesStatic data
| Product type | Certificat Turbo Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ABIVAX |
| Issuer | Morgan Stanley |
| WKN | MD5DE7 |
| ISIN | DE000MD5DE75 |
| Date issued | 20/06/2022 |
| Strike | 4.318 € |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 7 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 15.54 € |
|---|---|
| Lowest since issue | 1.78 € |
Company Profile
Abivax develops innovative treatments modulating the body's natural immune system machinery to treat patients with chronic inflammatory diseases, viral infections and cancer.
As a clinical-stage company, Abivax leverages its immune enhancing and antiviral platforms to optimize and develop drug candidates to treat ulcerative colitis, Crohn's disease, rheumatoid arthritis, and other inflammatory diseases (ABX464) as well as liver cancer (ABX196). The Company's mission is to utilize its drug development platforms to bring innovative and effective solutions to patients in these therapeutic areas with significant unmet needs.
Sector
-
Consensus: Abivax
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
12.72
EUR
Average target price
36.34
EUR
Spread / Average Target
+185.69%
- Stock Market
- Certificates
- Certificat
